NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PolyPid Ltd. (PYPD) Stock Analysis

PolyPid Ltd. (PYPD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PYPD

$5.39

+$0.12 (+2.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PYPD with… →

PYPD Key Statistics

As of Sep 4, 2026
Trading
Open
$5.30
Previous Close
$5.27
Day's Range
5.21–5.44
52-Week Range
3.06–5.73
Volume
73.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$109.48M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.31
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
20.31M
1-Year Return
+58.53%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
214.00K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PYPD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.19%
2025+42.76%
2024−20.00%
2023−81.85%
2022−87.84%
2021−42.02%
2020 (partial year)−47.89%

As of September 4, 2026.

PYPD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.17M—
2024$0.00−$29.02M—
2023$0.00−$23.87M—
2022$0.00−$39.56M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$32.97M−$34.17M—
2024$0.00—−$28.03M−$29.02M—
2023$0.00—−$22.87M−$23.87M—
2022$0.00—−$38.89M−$39.56M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PYPD Valuation vs Biotechnology Median

Median of 656 stocks
MetricPYPDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

PolyPid Ltd. (PYPD) is capitalised at $109.48M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 69.

PYPD last closed at $5.39 on September 4, 2026. That is +$0.12 (+2.28%) against the previous close. The 52-week range on file runs from $3.06 to $5.73. The latest close sits 76.14% above that 52-week low.

Financial Health

In fiscal 2025, PolyPid Ltd. reported revenue of $0.00. The same year closed with a net loss of $34.17M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +58.53%. Across 5 years the annualized return works out at −53.77%. The reported beta is 1.42. Daily returns over the trailing 6 years annualize to a volatility of 84.25%.

Growth & Income

No dividend is on file for PYPD.

Across the complete calendar years on file, 2025 returned +42.76% and 2022 returned −87.84%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +24.19%.

Peer Comparison

PolyPid Ltd. (PYPD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PolyPid Ltd. PYPD $109.48M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PolyPid Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PolyPid Ltd.

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Visit website →